Advances in the current treatment of autoimmune hepatitis (Q38000056)

26 August 2017

title

Advances in the current treatment of autoimmune hepatitis (English)

1 reference

26 August 2017

Albert J Czaja

1

1 reference

26 August 2017

publication date

3 April 2012

1 reference

Digestive Diseases and Sciences

26 August 2017

published in

1 reference

26 August 2017

volume

57

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

1996-2010

1 reference

Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Favorable outcomes of autoimmune hepatitis in a community clinic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Diagnosis and management of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Treatment challenges and investigational opportunities in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Current and future treatments of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Budesonide in previously untreated autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Budesonide induces complete remission in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

The use of budesonide in the treatment of autoimmune hepatitis in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Budesonide for the treatment of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil for autoimmune hepatitis: a single practice experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Diagnosis and treatment of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis. Part A: pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoantibodies as prognostic markers in autoimmune liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Rapidity of treatment response and outcome in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Hypothesis: The Aging Paradox and Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Reciprocal change with age in antibody to extrinsic and intrinsic antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Significance of antibodies to soluble liver antigen/liver pancreas: a large French study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis in special patient populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis in African Americans: presenting features and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

The impact of ethnicity on the natural history of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis in a North American Aboriginal/First Nations population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

An unusual form of autoimmune hepatitis in young Somalian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Racial disparity in liver disease: Biological, cultural, or socioeconomic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis following hepatitis A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Genetic distinctions between autoimmune hepatitis in Italy and North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis: the dilemma of rare diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Therapeutic strategies for autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Inhibitors of the calcineurin/NFAT pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

NFAT and NF-kappaB factors-the distant relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

NFAT proteins: key regulators of T-cell development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Immunosuppressive drugs: the first 50 years and a glance forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Molecular aspects of cyclophilins mediating therapeutic actions of their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

A risk-benefit assessment of tacrolimus in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

De novo autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Antifibrotic actions of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Mycophenolate mofetil--is it worth the cost? The in-favor opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Cost-effectiveness of pharmacotherapy for autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Difficult treatment decisions in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

CTLA-4: a key regulatory point in the control of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

T-cell-targeted therapies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

CD4+CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Epidemiology and estimated population burden of selected autoimmune diseases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2151-2

Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature

21 January 2018

1 reference

12 December 2020

Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis

1 reference

12 December 2020

An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses

1 reference

12 December 2020

Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1.

1 reference

12 December 2020

N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis

1 reference

12 December 2020

1 reference

12 December 2020

Significance of HLA DR4 in type 1 autoimmune hepatitis

1 reference

12 December 2020

In utero exposure to mycophenolate mofetil: A characteristic phenotype?

1 reference

12 December 2020

Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment

1 reference

12 December 2020

Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay

1 reference

12 December 2020

Failure of customary treatment in chronic active liver disease: causes and management

1 reference

12 December 2020

Observer variation in assessment of liver biopsies including analysis by kappa statistics.

1 reference

12 December 2020

Prevalence of autoimmune liver disease in Alaska Natives

1 reference

12 December 2020

Burden of liver disease in the United States: summary of a workshop

1 reference

12 December 2020

Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis

1 reference

12 December 2020

Mechanisms of action of mycophenolate mofetil

1 reference

12 December 2020

Diverse manifestations and evolving treatments of autoimmune hepatitis.

1 reference

12 December 2020

Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy

1 reference

12 December 2020

Abatacept for rheumatoid arthritis

1 reference

12 December 2020

Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis

1 reference

12 December 2020

Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis

1 reference

12 December 2020

Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome.

1 reference

12 December 2020

Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis

1 reference

12 December 2020

Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen

1 reference

12 December 2020

Severe chronic active liver disease. Prognostic significance of initial morphologic patterns

1 reference

12 December 2020

Azathioprine for long-term maintenance of remission in autoimmune hepatitis

1 reference

12 December 2020

Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis

1 reference

12 December 2020

Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis

1 reference

12 December 2020

Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly

1 reference

12 December 2020

Features and consequences of untreated type 1 autoimmune hepatitis

1 reference

12 December 2020

Prenatal exposure to mycophenolate mofetil: an updated estimate.

1 reference

12 December 2020

Consequences of treatment withdrawal in type 1 autoimmune hepatitis

1 reference

12 December 2020

Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.

1 reference

12 December 2020

Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis

1 reference

12 December 2020

Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology

1 reference

12 December 2020

Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis

1 reference

12 December 2020

Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor β on human intrahepatic fibroblasts cultured in vitro

1 reference

12 December 2020

Cyclosporine immunosuppression

1 reference

12 December 2020

Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution

1 reference

12 December 2020

Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype

1 reference

12 December 2020

Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis

1 reference

12 December 2020

Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis

1 reference

12 December 2020

Cyclosporin, a new treatment for autoimmune chronic active hepatitis

1 reference

12 December 2020

Follow-up of children with autoimmune hepatitis treated with cyclosporine

1 reference

12 December 2020

Pathogenesis of autoimmune hepatitis

1 reference

12 December 2020

Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis

1 reference

12 December 2020

T-cell function in aging: mechanisms of decline

1 reference

12 December 2020

Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal

1 reference

12 December 2020

Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis

1 reference

12 December 2020

10.1007/S10620-012-2151-2

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1022227509

0 references

1 reference